



EZTRACK

REVOLUTIONIZING EPILEPSY TREATMENT
WITH PREDICTIVE EEG ANALYTICS




Neurologic

CLINICAL PROBLEM



- 40M people suffer from focal epilepsy
- Seizures start in the brain in the Epileptogenic Zone (EZ)
- Cannot be cured with drugs
- Requires accurate identification of the EZ followed by brain surgery to remove the EZ

VERY LOW SUCCESS RATES



LOCATE EZ NON-INVASIVELY

- Monitors scalp signals
- Surgeons don't rely on it
- Indicates hemisphere or lobe of EZ- coarse

LOCATE EZ INVASIVELY

- Inhumane, lengthy, risky process
- Only 15% of patients elect to do it
- Requires EEG expertise


SURGERY TO REMOVE THE EZ

- 30-70% success rates
- Major post-surgery complications if the EZ is not accurately identified


LOCATING EZ NON-INVASIVELY

IS TOO COARSE, CAN ONLY PINPOINT EZ HEMISPHERE


PET SCAN




MRI




SPECT



Scalp EEG data is too noisy to precisely locate the EZ.





SCALP EEG







LOCATING EZ INVASIVELY IS OFTEN REQUIRED BUT PRONE TO HUMAN ERROR

CRANIOTOMY



ELECTRODE IMPLANTATION






MONITORING (DAYS/WEEKS)



Clinicians visually inspect hours of EEG data and look for abnormal activity channel by channel.

CLINICAL TEAM ATTEMPTS TO LOCALIZE VISUALLY





CHALLENGES WITH CURRENT PRACTICE

HIGH DEGREE OF PROCESS VARIABILITY

Electrodes must be implanted in the right place

PROLONGED HOSPITAL STAY

Requires days to weeks to observe many seizures

SUBJECTIVE DECISION CRITERIA

No data analytics to interpret signals

OUTCOMES HIGHLY VARIABLE

only 30-70% success


HIGH RISK, HIGH COST

Larger brain area removed to compensate for localization uncertainty; infection risk; \$200,000 per treatment





OUR SOLUTION - EZTRACK

CONVERTS EEG TO A SIMPLE HEAT MAP TO LOCALIZE EZ



EZTRACK

SMART EEG ANALYTICS:
BRAIN NETWORK-BASED
MODEL PREDICTIONS




>20% IMPROVEMENT IN
PREDICTED OUTCOMES




RETROSPECTIVE STUDIES



FRAGILITY MAP AGREES WITH CLINICIAN SUCCESSFUL OUTCOME





O': OrbitoFrontal
 G': Anterior Cingulate
 X': Mid Cingulate
 F': Fronto polar
 L': Lesion?
 N': Sup Frontal gyrus





Targeted laser ablation



FRAGILITY MAP DISAGREES WITH CLINICIAN FAILED OUTCOME




FRAGILITY MAP DISAGREES WITH CLINICIAN FAILED OUTCOME



FRAGILITY MAP AGREES WITH CLINICIAN SUCCESSFUL OUTCOME





- onset
- early spread
- late spread





FRAGILITY MAP DURING SLEEP



NO SEIZURE





FRAGILITY MAP DURING WAKE NO SEIZURE



FRAGILITY MAP DISAGREES WITH CLINICIAN FAILED OUTCOME




FRAGILITY MAP FOR SCALP SUCCESSFUL OUTCOME




FRAGILITY MAP FOR SCALP SUCCESSFUL OUTCOME


Fragility Map



Raw EEG





DOES FRAGILITY TELL US SOMETHING NEW?




FRAGILITY OF CLINICAL EZ VERSUS REST

Clinically annotated EZ




FRAGILITY OF CLINICAL EZ VERSUS REST

Success Cases






Failed Cases





FRAGILITY OF CLINICAL EZ VERSUS REST


Successes



Failures







FRAGILITY OF CLINICAL EZ VERSUS REST





Hypothesis: Fragility ratio (FR) is high for successes and low for failures

FRAGILITY RATIO PREDICTS OUTCOMES





FRAGILITY IS NOT THE SAME AS CLINICAL EEG SIGNATURES

High Frequency Oscillations (HFOs)



Low Voltage Fast Activity (LVFA)



\$500+M/YEAR REVENUE OPPORTUNITY (NORTH AMERICA)

5

of clinics that treat 80% of all epilepsy patients

(Cleveland Clinic, Jefferson Hospital, Massachusetts General, Mayo Clinic, Emory Hospital)

170,000

scans per year for all 5 clinics (scalp and invasive)

\$3,500

estimated price per EZTrack scan (similar to MRI pricing model)

\$500+M

**Annual revenue opportunity
SaaS based model**



RAISING \$200K FOR NEXT MILESTONES

GET FDA 510K APPROVAL

- Required to perform prospective trails at Jefferson Hospital, Cleveland Clinic

PRODUCTIZE THE SOLUTION

- Productize user interface
- Integrate into the clinical workflow

BUSINESS DEVELOPMENT

- Develop collateral
- Approach next set of potential customers - Massachusetts General, Mayo Clinic, Emory Hospital

\$750,000

**LEAD INVESTMENT FROM
THE NATIONAL SCIENCE FOUNDATION**

**ADDITIONAL
\$200,000**

SOUGHT FROM ANGEL INVESTORS

TEAM NEUROLOGIC



Sridevi Sarma, PhD
President & Co-founder

- Electrical Engineer (MIT)
- Associate Professor, Biomedical Engr (JHU)
- Complex Systems, Data Science, Neuroscience

Jorge Gonzalez-Martinez, MD PhD
Co-founder & Domain Expert

- Epilepsy Surgery (world leader)
- Neuroscience (University of São Paulo)

Adam Li
Co-founder & Acting CTO

- Biomedical Engineer (JHU)
- Bioinformatics

Bobby Norton
Product Manager

- Computer Science
- Tested Minds - Co-Founder and Principal Consultant

John Gale, PhD
Advisor

- Biology, PhD (Kent State)
- Electrophysiology, Neuromedical devices




Technology


Observation: seizure occurs in an *unstable* network

Title goes here

Non-Seizure




Seizure




Title goes here

Node 1





Title goes here

Node 1




Title goes here

Node 1



Title goes here

Node 1







Title goes here


Node 1

amount of change in connections
from node $i = \textit{fragility of node } i$



Title goes here

The most *fragile* nodes in the epileptic network correspond to the epileptogenic zone.



Title goes here

Thank You

